PHESGO is an FDA-approved treatment for HER2+ breast cancer. Whether your breast cancer is early or metastatic, PHESGO could be the treatment option that’s right for you.
PERJETA and Herceptin are two HER2-targeted therapies. They work together to treat HER2+ breast cancer alongside chemotherapy. PHESGO works the same in the way that it treats HER2+ breast cancer. Learn more about how PHESGO is thought to work. >
PERJETA + Herceptin are given over an approximate time span of 1 to 2.5 hours through an IV. PHESGO is given differently. It’s a single ~5 minute injection given under the skin.*
*The first dose is given in ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
In a clinical study, 85% of people preferred PHESGO over PERJETA + Herceptin and the most common reason was less time spent in the clinic. Check out the study here. >
Here are some ways to start the conversation:
Keeping an open dialogue with your doctor is key. Here are some other important questions to ask.
Here are some ways to start the conversation:
Keeping an open dialogue with your doctor is key. Here are some other important questions to ask.
Here are some ways to start the conversation:
Keeping an open dialogue with your doctor is key. Here are some other important questions to ask.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.